Showing results (111-120 of 225) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Lawrence S Blaszkowsky, David P Ryan, et al.
Clinical Biochemistry|December 25, 2012
Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosisMiriam J Smith, Sonia Esparza, Vanessa L Merker, et al.
Journal of Palliative Medicine|May 12, 2016
Cost Analysis of a Randomized Trial of Early Palliative Care in Patients with Metastatic Nonsmall-Cell Lung CancerJoseph A Greer, Angela C Tramontano, Pamela M McMahon, et al.
The Oncologist|May 7, 2022
Phase II Study of Cabozantinib in Patients With Bone MetastasisEdwin Choy, Gregory M Cote, M Dror Michaelson, et al.
Plos One|May 13, 2021
Isolation of intact extracellular vesicles from cryopreserved samplesShannon N Tessier, Lauren D Bookstaver, Cindy Angpraseuth, et al.
Contemporary Clinical Trials|August 29, 2022
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related painJennifer L W Da, Vanessa L Merker, Justin T Jordan, et al.
JCO Oncology Practice|November 9, 2022
Patients With Serious Mental Illness Can Engage in Tobacco Treatment Trials and Tobacco Cessation Interventions During Cancer TreatmentEleanor B Steffens, Elyse R Park, Alona Muzikansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Neuro-Oncology|April 13, 2019
Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivoSherif G Ahmed, Ahmed Abdelnabi, Casey A Maguire, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Pageof 23